OLMESARTAN/ AMLODIPINE HCT INTAS 40/5/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/12.5 mg film-coated tablet blister pack

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

olmesartan medoxomil, Quantity: 40 mg; amlodipine besilate, Quantity: 6.95 mg; hydrochlorothiazide, Quantity: 12.5 mg

Disponível em:

Accord Healthcare Pty Ltd

Forma farmacêutica:

Tablet, film coated

Composição:

Excipient Ingredients: lactose monohydrate; isopropyl alcohol; pregelatinised maize starch; povidone; silicified microcrystalline cellulose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350

Via de administração:

Oral

Unidades em pacote:

30 Tablets, 10 tablets

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

OLMESARTAN/ AMLODIPINE HCT Intas is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. This fixed dose combination is not indicated for initial therapy.

Resumo do produto:

Visual Identification: Light yellow, round, bevel-edged, film-coated tablets debossed with OC2 on one side and plain on other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Status de autorização:

Registered

Data de autorização:

2019-11-21